Wedbush Maintains Outperform on Solid Biosciences, Lowers Price Target to $16

Benzinga Newsdesk www.benzinga.com Negative 93.7%

Neg 93.7% Neu 0% Pos 0%

Wedbush analyst Laura Chico maintains Solid Biosciences (NASDAQ:SLDB) with a Outperform and lowers the price target from $17 to $16.